{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:56:21Z","timestamp":1790052981736,"version":"4.0.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2019.00612","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T04:19:05Z","timestamp":1568175545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples"],"prefix":"10.3389","volume":"10","author":[{"given":"Trevor E.","family":"Angell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maisie L.","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund S.","family":"Cibas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua E.","family":"Babiarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Sean","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Kloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia C.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Waguespack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"E364","DOI":"10.1210\/jc.2012-2703","article-title":"Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS","volume":"98","author":"Agrawal","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11242","DOI":"10.18632\/oncotarget.3593","article-title":"New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma","volume":"6","author":"Costa","year":"2015","journal-title":"Oncotarget"},{"key":"B5","doi-asserted-by":"publisher","first-page":"69638","DOI":"10.18632\/oncotarget.11922","article-title":"Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma","volume":"7","author":"Jung","year":"2016","journal-title":"Oncotarget"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12859-015-0849-9","article-title":"The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes","volume":"17","author":"Pagan","year":"2016","journal-title":"BMC Bioinform."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1093\/hmg\/ddw056","article-title":"Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations","volume":"25","author":"Pan","year":"2016","journal-title":"Hum Mol Genet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.ajhg.2016.04.014","article-title":"Genomic profiling of thyroid cancer reveals a role for thyroglobulin in metastasis","volume":"98","author":"Siraj","year":"2016","journal-title":"Am J Hum Genet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1006239","DOI":"10.1371\/journal.pgen.1006239","article-title":"Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers","volume":"12","author":"Yoo","year":"2016","journal-title":"PLoS Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"45784","DOI":"10.18632\/oncotarget.17412","article-title":"Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","first-page":"15533","DOI":"10.1038\/ncomms15533","article-title":"The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing","volume":"8","author":"Ye","year":"2017","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ccell.2018.07.002","article-title":"Integrated genomic analysis of hurthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes","volume":"34","author":"Ganly","year":"2018","journal-title":"Cancer Cell."},{"key":"B13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ccell.2018.06.013","article-title":"Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in hurthle cell carcinoma","volume":"34","author":"Gopal","year":"2018","journal-title":"Cancer Cell."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1210\/js.2018-00180","article-title":"Navigating systemic therapy in advanced thyroid carcinoma: from standard of care to personalized therapy and beyond","volume":"2","author":"Rao","year":"2018","journal-title":"J Endocr Soc"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/0008-5472.CAN-17-1925","article-title":"Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers","volume":"78","author":"Untch","year":"2018","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"E755","DOI":"10.3390\/ijms20030755","article-title":"mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B22","first-page":"28","article-title":"Clinical activity of selective RET inhibitor, BLU-667, in advanced RET-altered thyroid cancers: updated results from the phage 1 ARROW study (short call oral 5)","author":"Hu","year":"2018","journal-title":"Thyroid"},{"key":"B23","first-page":"28","article-title":"Clinical activity of LOXO-292, a highly selective RET inhibitor, in patients with RET-altered thyroid cancers (short call oral 6)","author":"Wirth","year":"2018","journal-title":"Thyroid"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jamasurg.2018.1153","article-title":"Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules","volume":"153","author":"Patel","year":"2018","journal-title":"JAMA Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.22132","article-title":"Extending expressed RNA genomics from surgical decision making for cytologically indeterminate thyroid nodules to targeting therapies for metastatic thyroid cancer","author":"Ali","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/thy.2017.0500","article-title":"The 2017 bethesda system for reporting Thyroid Cytopathology","volume":"27","author":"Cibas","year":"2017","journal-title":"Thyroid"},{"key":"B28","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/jclinpath-2016-204022","article-title":"Thyroid cytology-histology correlation using the RCPath terminology for thyroid cytology reporting","volume":"70","author":"Parkinson","year":"2017","journal-title":"J Clin Pathol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1089\/thy.2018.0726","article-title":"Independent comparison of the afirma genomic sequencing classifier and gene expression classifier for cytologically indeterminate Thyroid Nodules","volume":"29","author":"Angell","year":"2019","journal-title":"Thyroid"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1089\/thy.2018.0733","article-title":"Afirma gene sequencing classifier compared to gene expression classifier in indeterminate Thyroid Nodules","volume":"29","author":"Endo","year":"2019","journal-title":"Thyroid"},{"key":"B31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4158\/EP-2018-0395","article-title":"Statistical comparison of afirma gsc and afirma gec outcomes in a community endocrine surgical practice: early findings","volume":"25","author":"Harrell","year":"2019","journal-title":"Endocr Pract"},{"key":"B32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1101\/120295","article-title":"STAR-Fusion: fast and accurate fusion transcript detection from RNA-Seq","author":"Haas","year":"2017","journal-title":"bioRxiv."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","article-title":"A framework for variation discovery and genotyping using next-generation DNA sequencing data","volume":"43","author":"DePristo","year":"2011","journal-title":"Nat Genet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr Protoc Bioinformatics."},{"key":"B37","first-page":"371","article-title":"Machine learning from concept to clinic: reliable detection of BRAF V600E DNA mutations in thyroid nodules using high-dimensional RNA expression data","author":"Diggans","year":"2015","journal-title":"Pac Symp Biocomput"},{"key":"B38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa1203208","article-title":"Preoperative diagnosis of benign thyroid nodules with indeterminate cytology","volume":"367","author":"Alexander","year":"2012","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1089\/thy.2018.0791","article-title":"GLIS rearrangement is a genomic hallmark of hyalinizing trabecular tumor of the Thyroid Gland","volume":"29","author":"Nikiforova","year":"2019","journal-title":"Thyroid"},{"key":"B40","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3389\/fendo.2018.00566","article-title":"Clinical significance of thyroid-stimulating hormone receptor gene mutations and\/or sodium-iodine symporter gene overexpression in indeterminate thyroid fine needle biopsies","volume":"9","author":"Guan","year":"2018","journal-title":"Front Endocrinol."},{"key":"B41","first-page":"A105","article-title":"Clinical validation of the afirma genomic sequencing classifier for medullary thyroid cancer (Clinical Oral Abstract 29)","volume":"27","author":"Randolph","year":"2017","journal-title":"Thyroid"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/cncr.29934","article-title":"Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients","volume":"122","author":"Song","year":"2016","journal-title":"Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000477987","article-title":"Neoadjuvant vemurafenib in patients with locally advanced papillary thyroid cancer (abstract)","volume":"6","author":"Cabanillas","year":"","journal-title":"Eur Thyroid J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1089\/thy.2018.0060","article-title":"Neoadjuvant BRAF- and immune-directed therapy for anaplastic Thyroid carcinoma","volume":"28","author":"Cabanillas","year":"2018","journal-title":"Thyroid"},{"key":"B45","doi-asserted-by":"publisher","first-page":"74897","DOI":"10.18632\/oncotarget.20451","article-title":"Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma","volume":"8","author":"Szymonek","year":"2017","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","first-page":"E2297","DOI":"10.1210\/jc.2012-1923","article-title":"Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules","volume":"97","author":"Walsh","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/hed.25165","article-title":"Impact of oncogene panel results on surgical management of cytologically indeterminate thyroid nodules","volume":"40","author":"Valderrabano","year":"2018","journal-title":"Head Neck"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00612\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T04:19:09Z","timestamp":1568175549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00612\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":47,"alternative-id":["10.3389\/fendo.2019.00612"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2019.00612","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"article-number":"612"}}